Immunoreactivity for p27(kip1) and cyclin E is an independent predictor ofsurvival in primary gastric non-Hodgkin's lymphoma

Citation
Ajm. Ferreri et al., Immunoreactivity for p27(kip1) and cyclin E is an independent predictor ofsurvival in primary gastric non-Hodgkin's lymphoma, INT J CANC, 94(4), 2001, pp. 599-604
Citations number
20
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
INTERNATIONAL JOURNAL OF CANCER
ISSN journal
00207136 → ACNP
Volume
94
Issue
4
Year of publication
2001
Pages
599 - 604
Database
ISI
SICI code
0020-7136(20011115)94:4<599:IFPACE>2.0.ZU;2-C
Abstract
Our aim was to assess the prognostic implications of the expression of p27( KIP1) and cyclin E in gastric lymphoma. We investigated the prognostic valu e of the immunoreactivity of these molecules in 92 cases of primary gastric lymphoma: 34 LGMLs, 24 DLCLMLs and 34 DLCLs. p27 was positive in 88% of LG MLs, 71% of DLCLMLs and 32% of DLCLs (p = 0.004); cyclin E was positive in 9%, 33% and 59% of cases, respectively (p < 0.00001). p27/cyclin E immunore activity significantly correlated with histologic category, stage and LDH s erum level. p27 immunoreactivity was significantly associated with better s urvival, whereas cyclin E reactivity was significantly related to worse out come. Five-year CSS was 94% for patients with P27(+)/cyclin E- phenotype (n = 42), 79% for p27(+)/cyclin E+ (n = 14) or p27(-)/cyclin E- (n = 16) phen otype and 60% for p27(-)/cyclin E- phenotype (n = 16) (p = 0.02). The progn ostic role of p27/cyclin E expression was confirmed when analyzed separatel y within LGMLs and large-cell lymphomas. Immunoreactivity for p27 and cycli n E is an independent predictor of survival in PGLs that may be an adjuncti ve tool in identifying high-risk patients. It correlates with histologic ca tegory, stage and LDH serum level. p27(-)/cyclin E+ phenotype is associated with worse survival, probably due to a synergistic effect of both cell-cyc le defects. The predictive role of these molecules within each histologic g roup of PGLs deserves to be confirmed in larger series. (C) 2001 Wiley-Liss , Inc.